Chester County News and Community Website
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) reported fourth-quarter and full-year 2025 financial results while advancing its MOLBREEVI program, including a filed Biologics License Application with the U.S. Food and …
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration does not plan to convene an advisory committee for its review of the MOLBREEVI biologics license …
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said the U.S. Food and Drug Administration has accepted for review its biologics license application for MOLBREEVI as a treatment for autoimmune pulmonary …
Savara’s MOLBREEVI BLA Receives FDA Priority Review Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) granted stock options and restricted stock units covering a total of 15,000 shares to a newly hired employee on February 10, 2026, the …
Savara Grants Inducement Equity Awards to New Employee Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has amended its loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), unlocking significant non-dilutive financing tied to a pending …
Savara Secures Path to $150M as FDA Decision Nears for Rare Lung Drug Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has issued inducement equity awards to two newly hired employees, a move aimed at bolstering its workforce as the company pushes …
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug Read More LANGHORNE, PA — PANTHERx Rare Pharmacy and Savara Inc. (Nasdaq: SVRA) announced an exclusive U.S. distribution agreement for MOLBREEVI, an investigational inhaled therapy under FDA review for a rare and …
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval …
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease Read More LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said members of its management team will present and hold one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference, a closely watched …
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug Read More LANGHORNE, PA — Savara Inc. (NASDAQ: SVRA) said European patent authorities have moved to grant a key patent covering the liquid formulation of its investigational lung therapy MOLBREEVI, strengthening the …
Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI Read More